Navigation Links
Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies

Biologists, chemists, clinicians from Harvard, Stanford, University of Washington, the Scripps Research Institute, and Massachusetts General

Hospital partner with top investor groups Technology bypasses current debate on ethical use of embryonic stem cells by using pharmaceutical medicines to modulate stem cells inside the body

and via the use of 'reprogrammed' adult stem cells

SEATTLE, Nov. 29 /PRNewswire/ -- A group of the nation's most respected leaders in stem cell biology today announced formation of Fate Therapeutics, a new biotechnology company developing drugs to control cell fate. Fate will harness the healing power of adult stem cells by using small molecule drugs to modulate cells in vivo (in the body) and by reprogramming mature adult cells into stem cells.

"Fate's approach is the dawn of a new day in medicine," said Dr. Ben Shapiro, retired Executive Vice President of Worldwide Basic Research, Merck Research Laboratories, and a member of Fate's Science Advisory Board.

"Revolutionary advances in stem cell research have shifted the entire debate. We are proving that adult stem cell proliferation and differentiation can be modulated in the human body, and we now have the ability to induce pluripotent stem cells from adult human tissue rather than relying on the use of stem cells derived from embryos."

The company expects to have a lead adult stem cell modulating drug, in a cancer-related indication, enter the clinic in 2008.

Fate Therapeutics' revolutionary platform is two-fold

The Fate platform focuses on both regenerative and reprogramming medicine. The Fate regenerative medicine platform involves developing drugs that awaken adult stem cells in the body to repair damaged cells and tissues. The Fate reprogramming medicine platform involves developing drugs to reprogram mature adult cells into stem cells which when differentiated can become healthy heart, bone, brain or other tissues.

Applications of these two approaches include treating the effects of neurological diseases such as Down syndrome, Alzheimer's and Parkinson's; healing damaged heart tissue after heart attacks; increasing bone and muscle strength in the severely frail; and protecting organs after infection or transplantation. Fate will also tackle devastating cancers, such as pancreatic and colorectal cancer, by developing drugs to prevent the expansion and maturation of cancer stem cells.

Fate's approach differs significantly from others working with stem cells

To date, most stem cell companies have focused on cell therapy using harvested cells from cord blood or other tissues. In contrast, Fate's approach focuses exclusively on traditional therapeutics, namely small molecules and protein therapeutics, to direct cell fate. In addition to its novel approach, Fate's work has potential broad application across all degenerative diseases, developmental disorders and cancers, and in enabling the creation of healthy patient-identical cells for transplantation.

"We have looked at investing in many stem cell companies, but the science and commercial reality just wasn't there yet," said Robert Nelsen, founding partner of ARCH Venture Partners, whose firm co-founded Fate. "Now is the perfect storm; the right biology breakthroughs; a targeted way to use real drugs; and the leading scientists, entrepreneurs, and investors -- all in the same company to develop breakthrough medicines."

Founders' breakthroughs are breathtaking in scope and implication

Fate's founders include researchers from across the United States and multiple scientific disciplines, including basic biology, biological chemistry and translational medicine. As authors of many of the most far-ranging breakthroughs in stem cell science, the team is defining the changes in the field:

-- Philip Beachy, Ph.D., Stanford University Institute for Stem Cell

Biology and Regenerative Medicine and HHMI has pioneered the use of

synthetic small molecules and natural products to manipulate activities

of developmental and stem cell signaling pathways in vitro and in vivo.

-- Sheng Ding, Ph.D., Scripps Research Institute, has worked on the

identification of small molecules and genes that control cell fate,

including cell reprogramming and differentiation. Dr. Ding's work has

important implications for the development of small molecule drugs that

can potentiate adult stem cells in vivo, and reprogram differentiated

cells to new functions.

-- Randall Moon, Ph.D., University of Washington, Director, Institute for

Stem Cell and Regenerative Medicine, HHMI, and UW Department of

Pharmacology, has focused on illuminating the biological pathways that

control adult stem cells during the process of regeneration to develop

new therapeutic methods to activate regeneration.

-- David Scadden, M.D., Professor, Harvard University, Co-director and

Co-founder, Harvard Stem Cell Institute, Director Massachusetts

General Hospital Center for Regenerative Medicine, has broken new

ground in understanding how blood forming stem cells and other adult

stem cells are maintained in the adult body in specialized niches, and

in developing therapies that exploit this biology to modulate adult

stem cells in vivo.

-- Leonard Zon, M.D., Harvard University, Director of the Stem Cell

Program, Children's Hospital of Boston, and HHMI, is a world expert on

the biology of adult blood forming stem cells and methods of enhancing

their function for cancer and regenerative medicine applications

Esteemed scientists to join Fate's Science Advisory Board

In addition to the founding scientists, Fate Therapeutics has garnered the expertise of additional stem cell scientists, research leaders, and drug development luminaries to join its Scientific Advisory Board:

-- Robert Langer, Sc.D.: Institute Professor of Chemical and Biomedical

Engineering, Massachusetts Institute of Technology

-- Ram Sasisekharan, Ph.D.: Professor of Biological Engineering & Health

Sciences and Technology, Massachusetts Institute of Technology

-- Ben Shapiro, M.D.: Retired Executive Vice President of Worldwide Basic

Research, Merck Research Laboratories

"Fate's timing is excellent," said Fate's Executive Vice President Tom St. John. "The science is now mature enough. Clear therapeutic modalities have emerged, and the cloud of political and ethical debate surrounding embryonic stem cells is now a thing of the past. We've got a real opportunity to prove that Fate's adult stem cell therapies are the future of medicine."

Before joining Fate, St. John was the Vice President of Therapeutic Development at ICOS Corporation overseeing all of ICOS' development programs.

World-class investment team lined up behind scientists

The unparalleled scientific team is backed by leading venture capital firms ARCH Venture Partners, Polaris Venture Partners, Venrock and OVP, all with successful track records in building some of the world's leading life sciences companies.

The syndicate group has a combined $7 billion under management. Ground-breaking biotechnology companies founded by the firms and their partners include Immunex, IDEC Pharmaceuticals, Gilead Sciences, Genetics Institute, Illumina, Centocor, Sepracor, Alnylam Pharmaceuticals, Athena Neurosciences, Aviron, Corixa, deCode Genetics, Geron, Glycofi, Ikaria, Millennium Pharmaceuticals, Momenta Pharmaceuticals, Sirna Therapeutics, Trubion Pharmaceuticals, Vical and XenoPort.

Fate Therapeutics was co-founded by Alex Rives, of ARCH Venture Partners. The company's board of directors includes Amir Nashat, General Partner, Polaris Venture Partners; Robert Nelsen, Co-founder and Managing Director, ARCH Venture Partners; and Bryan Roberts, Managing General Partner, Venrock.

About Fate Therapeutics

Fate Therapeutics was founded by the world's leading experts in adult stem cell biology to develop and commercialize therapies to control the destiny of cells. The company's revolutionary platforms are focused on developing medicines that awaken adult stem cells resident within the body to fight disease and regenerate damaged cells and tissue, and on the use of small molecules to reprogram mature adult cells to an embryonic-like state. The company's work has broad application, and offers new hope in the treatment of degenerative diseases, developmental disorders, and cancer and in enabling the creation of patient-identical cells for transplantation.

Fate has facilities in Seattle, and soon in California and Massachusetts. For more information, see

SOURCE Fate Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and ... San Diego Rotary Club. The event entitled “Stem Cells and Their ... 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... ... October 09, 2017 , ... The ... medical marijuana products targeting the needs of consumers who are incorporating medical marijuana ... place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The ...
Breaking Biology Technology:
(Date:10/4/2017)... BLOOMINGTON, Ill. , Oct. 4, 2017  GCE Solutions, a ... powerful new data and document anonymization solution on October 4, 2017. ... the pharmaceutical field to comply with policy 0070 of the European ... documents and data. ... Innovation by GCE Solutions ...
(Date:6/30/2017)... , June 30, 2017 Today, ... developer and supplier of face and eye tracking ... Featured Product provider program. "Artificial ... innovative way to monitor a driver,s attentiveness levels ... from being able to detect fatigue and prevent ...
(Date:5/16/2017)... May 16, 2017  Veratad Technologies, LLC ( ... age and identity verification solutions, announced today they will ... 2017, May 15 thru May 17, 2017, in ... International Trade Center. Identity impacts the ... in today,s quickly evolving digital world, defining identity is ...
Breaking Biology News(10 mins):